Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kyoka Honma"'
Autor:
Mutsumi Akahane, Yuki Enoki, Reika Saiki, Yukitaka Hayashi, Kana Hiraoka, Kyoka Honma, Marina Itagaki, Mai Gotoda, Kozue Shinoda, Satomi Hanyu, Yuna Hamamura, Taichi Miyajima, Chihiro Ito, Kazuaki Taguchi, Shunsuke Uno, Yoshifumi Uwamino, Osamu Iketani, Naoki Hasegawa, Kazuaki Matsumoto
Publikováno v:
International Journal of Infectious Diseases, Vol 103, Iss , Pp 464-468 (2021)
Objectives: The long-term stability of antimicrobials dissolved in infusion solution is necessary to establish and spread the outpatient parenteral antimicrobial therapy (OPAT). In this study, we evaluated the stability of antimicrobial agents dissol
Externí odkaz:
https://doaj.org/article/8d862d177fd24687a1dccba6b18b299b
Autor:
Yuki Enoki, Yuki Igarashi, Yuki Watabe, Kyoka Honma, Yuto Suzuki, Yukitaka Hayashi, Kana Hiraoka, Kazuaki Taguchi, Kazuaki Matsumoto
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss , Pp 81-82 (2021)
Externí odkaz:
https://doaj.org/article/4cbca1b0aece4b39940e39b078976a57
Autor:
Chihiro Ito, Kazuaki Matsumoto, Osamu Iketani, Mutsumi Akahane, Yukitaka Hayashi, Reika Saiki, Kazuaki Taguchi, Kyoka Honma, Mai Gotoda, Yuna Hamamura, Kozue Shinoda, Marina Itagaki, Kana Hiraoka, Taichi Miyajima, Naoki Hasegawa, Shunsuke Uno, Yoshifumi Uwamino, Yuki Enoki, Satomi Hanyu
Publikováno v:
International Journal of Infectious Diseases, Vol 103, Iss, Pp 464-468 (2021)
Objectives The long-term stability of antimicrobials dissolved in infusion solution is necessary to establish and spread the outpatient parenteral antimicrobial therapy (OPAT). In this study, we evaluated the stability of antimicrobial agents dissolv
Autor:
Kazuaki Matsumoto, Yuki Watabe, Kana Hiraoka, Yukitaka Hayashi, Yuto Suzuki, Kazuaki Taguchi, Yuki Enoki, Kyoka Honma, Yuki Igarashi
Publikováno v:
Journal of Global Antimicrobial Resistance
Journal of Global Antimicrobial Resistance, Vol 24, Iss, Pp 81-82 (2021)
Journal of Global Antimicrobial Resistance, Vol 24, Iss, Pp 81-82 (2021)
Highlights • Remdesivir is proposed as a therapeutic for COVID-19 • Clinical improvement after remdesivir was higher compared with placebo • Remdesivir tended to reduce patient mortality rate, but this was not significant